Roche highly anticipated cancer immunotherapy fails in first late-stage trial
Tiragolumab works by selectively binding itself to TIGIT, a receptor found on immune system cells that normally serves to prevent an immune attack against healthy cells.
New Delhi: A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds.
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at email@example.com Contact no. 011-43720751